Close Menu

NEW YORK (GenomeWeb) – With US Food and Drug Administration clearance of Bio-Rad Laboratories' new clinical Droplet Digital PCR instrument and an assay to monitor treatment of chronic myeloid leukemia patients, the company now sees opportunities to rapidly grow the menu available on the clinical diagnostics system. The firm plans to add more oncology tests as well as noninvasive prenatal testing and newborn screening assays through both in-house development and partnerships with third-party assay makers.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Mar
27
Sponsored by
Swift Biosciences

Sequencing workflows require library quantification and normalization to ensure data quality and reduce cost. 

May
08
Sponsored by
Sysmex Inostics

This webinar will present recent evidence that demonstrates how incorporating circulating tumor DNA (ctDNA) assessments into real-world patient management can influence patient care decisions, alter radiographic interpretations, and impact clinical outcomes.